As we know irinotecan is an ABCB1 substrate, we hypothesized that cetuximab could effectively compete with chemotherapeutic agent binding to ABCB1 and thus increase intracellular drug accumulation in resistant cancer cells. The gene discussed is ABCB1; the disease is cancer.